On May 12, 2026 Incyte (Nasdaq:INCY) reported that data from key programs in its Hematology and Oncology franchises will be presented at the European Hematology Association (EHA) (Free EHA Whitepaper) 2026 Congress, to be held June 11 – 14, 2026, in Stockholm, Sweden.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"The breadth of the data that will be showcased at the 2026 EHA (Free EHA Whitepaper) Congress highlights the continued advancement of our Hematology and Oncology pipeline and our focus on delivering differentiated medicines for patients with cancer and hematologic diseases," said Pablo J. Cagnoni, M.D., President and Global Head of Research and Development, Incyte. "These presentations include findings from the frontMIND study, which support the U.S. and EU regulatory applications for tafasitamab (Monjuvi/Minjuvi) in patients with first-line diffuse large B-cell lymphoma (DLBCL). Additionally, data presentations for INCA033989, which support our Phase 3 trials, demonstrate the steady advancement of this molecularly targeted therapy that has the potential to revolutionize treatment for patients with myeloproliferative neoplasms (MPNs)."

Details on key data presentations at EHA (Free EHA Whitepaper) include:

Plenary Abstract Session

Tafasitamab

Tafasitamab Plus Lenalidomide and R-CHOP for Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Results From the Phase 3 frontMIND Study
(Plenary Abstract Session. June 13, 6:00 – 7:30 a.m. ET [12:00-1:30 p.m. CEST]. Abstract #S101.)

Oral Presentations

INCA033989 (mutCALR)

Mutant Calreticulin-Specific Monoclonal Antibody, INCA033989, is Well Tolerated and Achieves Robust Spleen, Anemia, and Molecular Responses in Patients with Myelofibrosis
(Session: Myeloproliferative neoplasms – Clinical. June 13, 11:15 a.m. – 12:30 p.m. ET [5:15-6:30 p.m. CEST]. Abstract #S216.)

Poster Presentations

INCA033989 (mutCALR)

Mutant Calreticulin-Specific Monoclonal Antibody, INCA033989, Produces Clonal Molecular Responses that Correlate with Clinical Responses in Patients with MF
(Poster Session 1- June 12, 12:45 – 1:45 p.m. ET [6:45 – 7:45 p.m. CEST], Abstract #PF884)

Mutant Calreticulin-Specific Monoclonal Antibody, INCA033989, is Well Tolerated and Achieves Rapid and Sustained Hematologic and Molecular Responses in Patients with Essential Thrombocythemia (ET)
(Poster Session 2- June 13, 12:45 – 1:45 p.m. ET [6:45 – 7:45 p.m. CEST], Abstract #PS1983)

INCA035784 (mutCALR)

Preclinical Evaluation of INCA035784, a Novel T-Cell–Redirecting Antibody for the Treatment of MutCALR-Driven Myeloproliferative Neoplasms (MPNs)
(Poster Session 1- June 12, 12:45 – 1:45 p.m. ET [6:45 -7:45 p.m. CEST], Abstract #PF858)

INCA160058 (JAK2V617F)

INCB160058 Selectively Targets JAK2V617F-driven Hematopoiesis in Diverse and Drug-Resistant Models of Myeloproliferative Neoplasms (MPNs)
(Poster Session 1- June 12, 12:45 – 1:45 p.m. ET [6:45 -7:45 p.m. CEST], Abstract #PF872)

Axatilimab

Assessments of Bone Health Among Patients with Chronic Graft-Versus-Host Disease Receiving Axatilimab in the AGAVE-201 Trial
(Poster Session 1- June 12, 12:45 – 1:45 p.m. ET [6:45 – 7:45 p.m. CEST], Abstract #PF1151)

Axatilimab in Combination with Ruxolitinib in Patients with Newly Diagnosed Chronic Graft-Versus-Host Disease: Updated Safety Analysis of a Randomized, Phase 2 Study
​(Poster Session 2- June 13, 12:45 – 1:45 p.m. ET [6:45 – 7:45 p.m. CEST], Abstract #PS2243)

Ponatinib

Efficacy and Safety of Ponatinib in Pediatric Patients With BCR::ABL–Positive Chronic Phase Chronic Myeloid Leukemia (CP-CML): Preliminary Results From the INCB84344-102 Study
(Poster Session 1- June 12, 12:45 – 1:45 p.m. ET [6:45 – 7:45 p.m. CEST], Abstract #PF628)

Ruxolitinib

Longitudinal Analysis of Iron Deficiency Markers in Patients with Polycythemia Vera Enrolled in the Prospective Observational REVEAL Study
(Poster Session 1- June 12, 12:45 – 1:45 p.m. ET [6:45 – 7:45 p.m. CEST], Abstract #PF910)

Risk factors for Progressive Kidney Impairment Among Patients with Polycythemia Vera (PV) are Recapitulated and Treatable in Mouse Models of PV
(Poster Session 1- June 12, 12:45 – 1:45 p.m. ET [6:45 – 7:45 CEST], Abstract #PF914)

AI-Quantified Bone Marrow Fibrosis and Megakaryocyte Features Correlate With Driver VAF and Outcomes in the MOST MPN Study
​(Poster Session 2- June 13, 12:45 – 1:45 p.m. ET [6:45 – 7:45 p.m. CEST], Abstract #PS1961)

Identification of Biomarkers to Predict Disease Progression Via Molecular Analysis of Patients (pts) with Low-Risk Myelofibrosis (MF) Enrolled in the MOST Study
(Poster Session 2- June 13, 12:45 – 1:45 p.m. ET [6:45 – 7:45 p.m. CEST], Abstract #PS1970)

Tafasitamab

Phase 3 inMIND trial of Tafasitamab (Tafa) plus Lenalidomide (Len) and Rituximab (R) in Relapsed/Refractory (R/R) Follicular Lymphoma (FL): Analyses of Biomarkers Predictive of Patient (pt) Response
(Poster Session 1- June 12, 12:45 – 1:45 p.m. ET [6:45 – 7:45 p.m. CEST], Abstract #PF1075)

Phase 3 inMIND Study Of Tafasitamab Plus Lenalidomide and Rituximab for Relapsed or Refractory Follicular Lymphoma: Clinical Characteristics and Outcomes of Patients Receiving Second-Line Treatment
(Poster Session 1- June 12, 12:45 – 1:45 p.m. ET [6:45 – 7:45 p.m. CEST], Abstract #PF948)

Phase 3 inMIND Study of Tafasitamab (Tafa) plus Lenalidomide (Len) and Rituximab (R) for Relapsed or Refractory Follicular Lymphoma (R/R FL): Outcomes in Patients With or Without High-risk Factors
(Poster Session 2- June 13, 12:45 – 1:45 p.m. ET [6:45 – 7:45 p.m. CEST], Abstract #PS2048)

Effectiveness and Safety of Chimeric Antigen Receptor T-Cell (CAR-T) Therapy After Tafasitamab (Tafa) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL): A Real-World Study
(Poster Session 2- June 13, 12:45 – 1:45 p.m. ET [6:45 – 7:45 p.m. CEST], Abstract #PS2089)

More information regarding the EHA (Free EHA Whitepaper) 2026 Congress can be found at: View Source

About Jakafi (ruxolitinib)
Jakafi (ruxolitinib) is a JAK1/JAK2 inhibitor approved by the U.S. FDA for the treatment of polycythemia vera (PV) in adults who have had an inadequate response to or are intolerant of hydroxyurea; intermediate or high-risk myelofibrosis (MF), including primary MF, post-polycythemia vera MF and post-essential thrombocythemia MF in adults; steroid-refractory acute GVHD in adult and pediatric patients 12 years and older; and chronic GVHD after failure of one or two lines of systemic therapy in adult and pediatric patients 12 years and older.

Jakafi is a registered trademark of Incyte.

About Monjuvi (tafasitamab-cxix)/Minjuvi (tafasitamab)
Monjuvi (tafasitamab-cxix)/Minjuvi (tafasitamab) is a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody. Tafasitamab incorporates an XmAb engineered Fc domain, which mediates B-cell lysis through apoptosis and immune effector mechanism including Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC) and Antibody-Dependent Cellular Phagocytosis (ADCP). Incyte licenses exclusive worldwide rights to develop and commercialize tafasitamab from Xencor, Inc.

In the U.S., Monjuvi is approved by the U.S. FDA in combination with lenalidomide and rituximab for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL).

Monjuvi is not indicated and is not recommended for the treatment of patients with relapsed or refractory marginal zone lymphoma outside of controlled clinical trials.

Additionally, Monjuvi received accelerated approval in the United States in combination with lenalidomide for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified, including DLBCL arising from low grade lymphoma, and who are not eligible for autologous stem cell transplant (ASCT).

In Europe, Minjuvi (tafasitamab) received conditional Marketing Authorization from the European Medicines Agency in combination with lenalidomide, followed by Minjuvi monotherapy, for the treatment of adult patients with relapsed or refractory DLBCL who are not eligible for ASCT.

Additionally, Minjuvi is approved in combination with lenalidomide and rituximab for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) (Grade 1-3a) after at least one line of systemic therapy in Europe.

In Japan, Minjuvi is approved in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL).

XmAb is a registered trademark of Xencor, Inc.

Monjuvi and Minjuvi are registered trademarks of Incyte.

About Niktimvo (axatilimab-csfr)
Niktimvo (axatilimab-csfr) is a first-in-class colony stimulating factor-1 receptor (CSF-1R)-blocking antibody approved for use in the U.S. for the treatment of chronic GVHD after failure of at least two prior lines of systemic therapy in adult and pediatric patients weighing at least 40 kg (88.2 lbs).

In 2016, Syndax licensed exclusive worldwide rights to develop and commercialize axatilimab from UCB. In September 2021, Syndax and Incyte entered into an exclusive worldwide co-development and co-commercialization license agreement for axatilimab in chronic GVHD and any future indications.

Axatilimab is being studied in frontline combination trials in chronic GVHD – a Phase 2 combination trial with ruxolitinib (NCT06388564) and a Phase 3 combination trial with steroids (NCT06585774) are underway. Axatilimab is also being studied in an ongoing Phase 2 trial in patients with idiopathic pulmonary fibrosis (NCT06132256).

Niktimvo is a trademark of Incyte.

All other trademarks are the property of their respective owners.

About Iclusig (ponatinib) tablets
Iclusig (ponatinib), targets not only native BCR-ABL but also its isoforms that carry mutations that confer resistance to treatment, including the T315I mutation, which has been associated with resistance to other approved tyrosine kinase inhibitors.

In the EU, Iclusig is approved for the treatment of adult patients with chronic phase, accelerated phase or blast phase chronic myeloid leukemia (CML) who are resistant to dasatinib or nilotinib; who are intolerant to dasatinib or nilotinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the T315I mutation, or the treatment of adult patients with Philadelphia-chromosome positive acute lymphoblastic leukemia (Ph+ ALL) who are resistant to dasatinib; who are intolerant to dasatinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the T315I mutation.

Incyte has an exclusive license from Takeda Pharmaceuticals International AG to commercialize ponatinib in the European Union and 29 other countries, including Switzerland, UK, Norway, Turkey, Israel and Russia. Iclusig is marketed in the U.S. by Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited.

(Press release, Incyte, MAY 12, 2026, View Source [SID1234665576])

On May 12, 2026 TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (the "Company"), an oncology company integrating novel delivery technology with standard of care therapies, and its investigational immunotherapeutic to transform treatment for patients with solid tumors, reported financial results for the quarter ended March 31, 2026, and provided an operational update.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"The first quarter marked an important strategic inflection point for TriSalus as we significantly strengthened our commercial infrastructure, expanded the clinical evidence supporting PEDD, and continued advancing our next-generation platform opportunities," said Mary Szela, President and Chief Executive Officer of TriSalus. "We are increasingly demonstrating that PEDD is not simply a device, but a differentiated therapeutic delivery platform capable of improving procedural outcomes, reducing healthcare utilization, and expanding treatment possibilities across multiple indications.

During and subsequent to the quarter, we added meaningful new clinical evidence supporting PEDD across liver embolization therapy for liver cancer, and other new embolization applications, including one of the largest real-world analyses ever conducted in interventional oncology. At the same time, we substantially completed the commercial expansion initiatives designed to support our next phase of growth and broader market penetration.

Our updated revenue outlook reflects the lower Q1 revenue from the commercial expansion and the delayed FDA clearance timing for TriNav Advance, our next-generation device which extends PEDD capability to small distal vessels via microcatheter. We continue to believe the long-term growth opportunity for the PEDD platform remains substantial."

Highlights for First Quarter 2026 and Recent Weeks

Reported publication of Real World PEDD Study of more than 16,800 patients (603 PEDD patients matched against 16,210 non-PEDD patients) published in Journal of Comparative Effectiveness Research, which found PEDD technology was associated with fewer post-procedure complications, reduced hospitalizations, and approximately $7,700 in per-patient charge avoidance despite PEDD patients having greater baseline clinical complexity.
Presented new clinical and preclinical data at the 2026 Society of Interventional Radiology Annual Scientific Meeting including a preclinical study showing enhanced hepatic tumor penetration during embolic sphere delivery, a clinical analysis of embolization in neuroendocrine tumor liver metastases before and after PEDD, and a clinical assessment of safety and efficacy in uterine artery embolization, further expanding the body of evidence supporting PEDD across multiple applications.
Reported publication of preclinical research in Frontiers in Oncology demonstrating enhanced delivery and immune activation with nelitolimod delivered with PEDD in liver tumor models.
Completed a public offering during the quarter, further strengthening the balance sheet with $46 million in gross proceeds and supporting the Company’s planned commercial expansion initiatives designed to support long-term growth and broader market opportunity.
Appointed veteran healthcare investor Michael P. Stansky to the Board of Directors in February 2026.
Announced the appointment of Richard Marshall, M.D., as Chief Medical Officer effective June 29, 2026.
Financial Results for Q1 2026

Revenue from the sale of the TriNav system, was $8.9 million for the three months ended March 31, 2026, a decrease of 2.9% compared to the same period in 2025. The decrease in revenue was primarily due to the Company’s commercial expansion.
Gross margins were 86.2% for the three months ended March 31, 2026, compared to 83.7% for the same period in 2025. The year-over-year increase in gross margin was primarily due to lower average cost per TriNav unit.
Operating losses were $8.4 million for the three months ended March 31, 2026, compared to losses of $7.3 million for the same period in 2025. The increase in operating losses was primarily driven by higher sales and marketing expenses related to our commercial expansion and an increase in non-cash stock-based compensation expense, partially offset by improved gross margins.
Net income available to common stockholders was $1.5 million for three months ended March 31, 2026, compared to a net loss of $11.1 million for the same period in 2025. The current period includes $11.3 million of non-cash gains related to changes in the fair value of various derivatives for the three months ended March 31, 2026, compared to losses of $1.7 million for the same period in 2025. The basic and diluted earnings (loss) per share for three months ended March 31, 2026, was $0.03, compared to $(0.39) for the same period in 2025.
The non-GAAP measure of adjusted EBITDA is shown in the table below as the Company believes it is an important measure of performance. Adjusted EBITDA losses were $5.8 million for the three months ended March 31, 2026, compared to losses of $5.5 million for the same period in 2025. The increase in adjusted EBITDA losses were primarily driven by higher stock-based compensation and increased operating expenses.
On March 31, 2026, cash and cash equivalents totaled $56.6 million. The Company raised $46.0 million in gross proceeds in the first quarter from an equity offering. The Company believes that these proceeds provide sufficient cash runway to fully fund commercial expansion and pipeline development.
Conference Call & Webcast

The Company will host a conference call and webcast today at 4:30 PM eastern time to discuss its financial results for the quarter ended March 31, 2026. Parties interested in participating by phone should register using the online form on our investor relations website. After registering for the webcast, dial-in details will be provided in an auto-generated e-mail containing a link to the conference phone number along with a personal pin. The event will also be webcast live on the investor relations section of TriSalus’ website. A replay will also be available on the website following the event.

(Press release, TriSalus Life Sciences, MAY 12, 2026, View Source [SID1234665575])

On May 12, 2026 SkylineDx, an innovative company specializing in molecular diagnostics for dermatology, reported data from two oral and one e-poster presentation, focusing on CSCC, at the 83rd Society for Investigative Dermatology Annual Meeting, taking place May 13-16, in Chicago. The presentations will showcase findings from a comprehensive genomic and transcriptomic characterization of CSCC, including driver mutations and genetic alterations in HLA class I genes, and a new gene expression signature associated with metastatic risk.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

CSCC is the second most common form of skin cancer worldwide1, and while most tumors are not life-threatening, 2-5% of patients develop metastases². A major unmet clinical need is to identify this subset of patients who will eventually develop metastatic disease. Achieving this has been challenging because CSCC is not included in most cancer registries and was left out of large-scale consortia projects. Within the framework of an international collaboration of top research institutions, the Erasmus Medical Center, Rotterdam, the University of California, San Francisco, and SkylineDx sought to characterize the genomic and transcriptomic drivers of CSCC metastasis to inform future development in clinical settings.

Oral Presentations:

"Comprehensive genomic characterization of cutaneous squamous cell carcinoma"

To better understand what causes some CSCCs to progress to metastatic disease, four national databases in the Netherlands were integrated to assemble a cohort of clinically annotated tumors linked to outcome. RNA-sequencing was performed on 366 tumors, and whole-exome sequencing was performed on 147 tumors. Findings provide a new, more detailed molecular picture of CSCC and identify which biomarkers can be associated with poor prognosis – providing better insights into tumor biology.

"Genetic alterations of HLA class I genes in cutaneous squamous cell carcinoma"

CSCCs exhibit high mutation burden and are highly immunogenic; however, mutations affecting antigen presentation have not been systematically characterized. To address this knowledge gap, the role of germline HLA diversity in cancer susceptibility was first examined. Next, it was investigated whether HLA genes are also subject to somatic selection during CSCC tumorigenesis. The findings suggest that a reduced baseline capacity for antigen presentation, inherited by germline HLA alleles, and/or the acquired loss of antigen presentation, through somatic alterations, promote keratinocyte carcinogenesis.

E-Poster:

"Gene expression predicts metastatic risk in low-risk cutaneous squamous cell carcinoma."

SCCore GEP, a novel gene expression signature for CSCC, addresses the need for improved metastatic risk stratification, as more than one-third of metastases occur in patients initially classified as "low risk" (T1, T2a), which represents 90% of patients. This SCCore GEP gene expression signature may enable more precise risk stratification by revealing biological risk factors that extend beyond traditional clinical and pathological features as represented by the staging systems.

"The Cancer Genome Atlas and other large-scale sequencing consortia overlooked CSCC, despite it being one of the most common forms of cancer Worldwide. Our study is the largest omics characterization of CSCC to date, which will serve as a major resource to the research community," said Hunter Shain, Associate Professor, Department of Dermatology and Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco. "Already, we have discovered promising biomarkers that complement and/or outperform established staging systems. I look forward to seeing how else this rich dataset will foster discovery in this historically neglected area of cancer research."

"CSCC patients stand to benefit from an improved risk stratification that can identify those at highest risk of poor outcomes, such as metastasis3," said SkylineDx CEO Dharminder Chahal. "Building on our experience in melanoma, we are striving to develop molecular diagnostic solutions for CSCC that enhance currently available risk stratification measures such as staging systems and nomograms based on clinicopathological factors, to ultimately improve patient outcomes."

(Press release, SkylineDx, MAY 12, 2026, View Source [SID1234665574])

On May 12, 2026 Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery powered by AI/ML, reported that management will present at the 2026 Stifel Virtual Targeted Oncology Forum. The presentation will take place on Tuesday, May 19, 2026, at 10:00-10:25 AM ET.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast will be accessible on the Investor Relations section of the Compugen website at www.cgen.com. A replay will also be available following the live event.

(Press release, Compugen, MAY 12, 2026, View Source [SID1234665573])

On May 12, 2026 Halia Therapeutics, Inc., a clinical-stage biopharmaceutical company developing first-in-class therapies targeting the NLRP3 inflammasome and related inflammatory pathways, reported final Phase 2 results for ofirnoflast (HT-6184) in patients with lower-risk myelodysplastic syndrome (LR-MDS). The data will be presented in an oral session at the European Hematology Association (EHA) (Free EHA Whitepaper) 2026 Hybrid Congress, June 11–14, 2026, in Stockholm, Sweden. The accepted abstract is available today on the EHA (Free EHA Whitepaper) Congress platform.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The company also announced the appointment of Han Myint, MD, FACP, as Chief Medical Officer. Dr. Myint will lead Halia’s global clinical development, medical affairs, and safety strategy as the company prepares to advance ofirnoflast into pivotal development and progresses its broader pipeline grounded in human genetic resilience and innate immune biology.

Final Phase 2 Results to Be Presented at EHA (Free EHA Whitepaper)2026

The open-label, single-arm Phase 2 trial enrolled 37 adults with IPSS-R very low- to intermediate-risk MDS (score ≤4.5) who had symptomatic anemia or red blood cell (RBC) transfusion dependence and were refractory to, intolerant of, or ineligible for erythropoiesis-stimulating agents (ESAs). Ofirnoflast was administered orally at 2 mg once daily on a 5-days-on/2-days-off schedule for up to 32 weeks. The primary endpoint was hematological improvement (HI) per IWG 2018 criteria. Highlights from the accepted abstract include:

67% overall HI rate among 30 evaluable patients, with multilineage activity: 62% HI-E, 60% HI-P, and 50% HI-N
55% RBC transfusion independence for ≥8 weeks among transfusion-dependent patients (10/18), with 39% sustained for ≥16 weeks
Median duration of transfusion independence of 28.5 weeks
75% HI-E among non-transfusion-dependent patients (9/12)
Median hemoglobin rise of 4.5 g/dL in HI-E and transfusion-independence responders (range 0.1–7.1 g/dL)
No treatment-related serious adverse events; treatment-related adverse events occurred in 27% of patients, with a single Grade ≥3 event (hypertension)
Activity observed across WHO MDS subtypes and mutational backgrounds, including patients with and without SF3B1 or del(5q)
Additional efficacy, safety, biomarker, and quality-of-life data will be presented at the EHA (Free EHA Whitepaper)2026 Congress.

"These final Phase 2 results validate our approach of targeting upstream innate immune biology in lower-risk MDS," said David J. Bearss, Ph.D., President, Chief Executive Officer, and co-founder of Halia Therapeutics. "Ofirnoflast has demonstrated durable transfusion independence, multilineage hematological improvement, and a favorable safety profile in a patient population with significant unmet need."

Han Myint, MD, FACP Appointed Chief Medical Officer

Dr. Myint brings more than three decades of experience spanning academic medicine, biotechnology and global pharmaceutical organizations, with deep expertise in hematologic malignancies, oncology drug development and late-stage clinical strategy.

Dr. Myint is an internationally recognized hematologist-oncologist and biopharmaceutical executive with more than three decades of experience spanning academic medicine, biotechnology and large pharmaceutical organizations. Throughout his career, he has led the development of innovative therapies across solid tumors, hematologic cancers and cellular immunotherapy programs, with experience advancing candidates from early-stage research through regulatory approval and commercialization.

"The addition of Han to our leadership team strengthens our ability to execute the next phase of the ofirnoflast development program with clinical and regulatory execution, as we advance toward pivotal development," continued Bearss. "He is one of the rare leaders who has worked across malignant hematology, global drug development, academic medicine, and late-stage commercialization. His experience in myeloid diseases, pivotal trial strategy, and regulatory engagement is directly aligned with where Halia is headed."

Commenting on his appointment, Dr. Myint said, "I am excited to join Halia at such a pivotal moment. The ofirnoflast Phase 2 data support a differentiated therapeutic approach in lower-risk MDS, where patients continue to need new oral options that can improve hematopoiesis and reduce transfusion burden. Halia’s broader platform, rooted in human genetic resilience and innate immune biology, provides a compelling foundation for developing medicines across serious hematologic and inflammatory diseases. I look forward to advancing ofirnoflast and the pipeline through the next stages of clinical development."

About Han Myint, MD, FACP

Dr. Myint is a hematologist-oncologist and drug-development leader with more than 30 years of experience across academia, biotechnology, and global pharmaceutical organizations. Previously, he was Chief Medical Officer of NextCure, Inc., overseeing first-in-human and proof-of-concept oncology trials, and Chief Medical Officer of NexImmune, Inc., a clinical-stage developer of T cell–based immunotherapies.

Earlier in his industry career, Dr. Myint held senior leadership roles at Celgene Corporation (now part of Bristol Myers Squibb), including Global Myeloid Disease Lead and Co-Chair of the Global Myeloid Franchise Team, where he contributed to the development, approval, and global launch of therapies for myeloid diseases including Thalassemia, MF, MDS and AML.

Before transitioning to industry, Dr. Myint was an academic hematologist-oncologist and stem cell transplant physician. He served as Professor of Medicine and Director of Stem Cell Transplantation and the Hematological Malignancies Program at the University of Colorado, Denver, where he built a FACT-accredited and Center of Excellence-designated stem cell transplant program. He previously held academic leadership roles at Rush University Medical Center. Dr. Myint received his MBBS from the Institute of Medicine in Yangon and completed postgraduate training in internal medicine and hematology in the United Kingdom, followed by advanced hematology/oncology and stem cell transplantation training in the United States. He is a fellow of the Royal College of Pathologists, London, UK, Royal College of Physicians & Surgeons, Glasgow, Royal College of Physicians of Edinburgh, and American College of Physicians.

EHA2026 Presentation Details

Title: Ofirnoflast, a First-in-Class NEK7 Inhibitor, Induces Robust Transfusion Independence and Multilineage Hematological Improvement in Lower-Risk Myelodysplastic Syndrome (LR-MDS): Phase 2 Results
Abstract number: S174
Session: Oral Session s426 — Myelodysplastic Syndromes – Clinical
Presenting author: Varun Bafna, MD
Date and time: Friday, June 12, 2026, 17:15–18:30 CEST
Location: A2-3 Hall, Stockholmsmässan, Stockholm, Sweden, and virtual on the EHA (Free EHA Whitepaper) Congress platform

About Ofirnoflast (HT-6184)

Ofirnoflast is Halia’s first-in-class, oral, allosteric NEK7 inhibitor designed to modulate NLRP3 inflammasome activation upstream of inflammatory signaling. By targeting NEK7 before NLRP3 assembly, ofirnoflast prevents inflammasome formation and disrupts a key pathway implicated in ineffective hematopoiesis. Halia is advancing ofirnoflast as a potential disease-modifying therapy for lower-risk MDS, with broader development opportunities across inflammasome-driven diseases.

(Press release, Halia Therapeutics, MAY 12, 2026, View Source [SID1234665572])